T-cell non-Hodgkin lymphoma
MONDO:0015760A non-Hodgkin lymphoma of T-cell lineage. It includes the T lymphoblastic lymphoma and the mature T- and NK-cell lymphomas. -- 2003
Also known as: T cell lymphoma, T-cell NHL, T-cell and NK-cell non-Hodgkin lymphoma, T-cell and NK-cell non-Hodgkin's lymphoma, T-cell lymphoma, T-cell non-Hodgkin lymphoma, T-cell non-Hodgkin's lymphoma, non-Hodgkin's T-cell lymphoma
2312 clinical trials for this condition and its sub-types, 98 tagged with T-cell non-Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of T-cell non-Hodgkin lymphoma
-
Mature T-cell and NK-cell non-Hodgkin lymphoma 150 trials · 240 incl. sub-types
8 sub-types
- Anaplastic large cell lymphoma 66 trials · 89 incl. sub-types Sub-types →
- Angioimmunoblastic T-cell lymphoma 58 trials
- T-cell large granular lymphocyte leukemia 18 trials
- T-cell prolymphocytic leukemia 17 trials
- Aggressive NK-cell leukemia 11 trials
- Breast implant-associated anaplastic large cell lymphoma 3 trials
- Hydroa vacciniforme-like lymphoma 3 trials
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
-
Primary cutaneous T-cell lymphoma 4 trials · 92 incl. sub-types
4 sub-types
-
T-lymphoblastic lymphoma 32 trials
-
CD4+/CD56+ hematodermic neoplasm 31 trials
-
Adult T-cell leukemia/lymphoma 31 trials
-
Enteropathy-associated T-cell lymphoma 20 trials
1 sub-type
-
Hepatosplenic T-cell lymphoma 16 trials
Most studied deeper sub-types
-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug cocktails aim to outsmart Hard-to-Treat T-Cell lymphomas
Disease control Not yet recruitingThis early-phase trial tests two different drug combinations for people with T-cell lymphoma that has come back or not responded to prior treatment. One group receives belinostat plus azacitidine; the other receives belinostat plus pralatrexate. The goal is to find the safest dos…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for rare blood cancers: drug cocktail targets tough lymphomas
Disease control Not yet recruitingThis study tests a new drug called zeprumetostat, combined with either golidocitinib or chidamide, in 60 adults with relapsed or refractory mature T-cell and NK-cell lymphomas. The goal is to find safe doses and see if the combination shrinks tumors. It is an early-phase trial, s…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New study aims to decode PTCL by genetic subtype
Knowledge-focused Not yet recruitingThis study will follow 1000 people diagnosed with peripheral T-cell lymphoma (PTCL) to see how different genetic subtypes affect disease progression and treatment response. Researchers will collect data from multiple hospitals and use genetic testing to classify patients. The goa…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Skin cancer study digs into patient data to spot trends
Knowledge-focused Not yet recruitingThis study looks back at the medical records of 350 adults diagnosed with cutaneous T-cell lymphoma, a rare type of skin cancer, treated at Hospital México in Costa Rica between 2019 and 2025. Researchers aim to describe the patients' backgrounds, the treatments they received, an…
Sponsor: Caja Costarricense de Seguro Social • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC